Blood vessels, a potential therapeutic target in rheumatoid arthritis?
New micro-vessels formation within synovium and macro-vessels endothelial damage with atheroma are two major features of rheumatoid arthritis, the former related to the articular involvement of the disease, the latter to its main systemic complication. The similarities between pannus development and solid tumors growth, and the efficacy of anti-angiogenic treatments in oncology, opened the perspective of directly targeting angiogenesis in arthritis. Nevertheless, despite the success of different anti-angiogenic therapeutic strategies in many arthritis experimental models, the application in human disease is still lacking. Recent data suggest that synovial neoangiogenesis and macro-vessels endothelial damage might be two linked phenomena. While synovial angiogenesis seems to be detrimental to endothelial damage repair, even anti-angiogenic treatments might paradoxically aggravate macro-vascular disease, especially in the context of uncontrolled inflammation. These elements induce to further explore the interconnections between inflammation and angiogenesis on one side and between micro- and macro-vascular diseases on the other, in order to establish the proper way to therapeutically target blood vessels in rheumatoid arthritis.
Semerano
Luca
L
Department of Rheumatology, Avicenne Hospital, AP-HP, Bobigny, France. luca.semerano@avc.aphp.fr
Clavel
Gaëlle
G
Assier
Eric
E
Denys
Anne
A
Boissier
Marie-Christophe
MC
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology*; D001808:Blood Vessels / Q000503:physiopathology*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology; D013583:Synovial Membrane / Q000098:blood supply
D020533:Angiogenesis Inhibitors